Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain

Trial Profile

Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Pain
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 24 May 2017 Status changed from active, no longer recruiting to completed.
    • 17 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
    • 25 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top